aTyr Pharma Inc
471A
Company Profile
Business description
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Contact
10240 Sorrento Valley Road
Suite 300
San DiegoCA92121
USAT: +1 858 731-8389
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
58
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,932.00 | 91.60 | 1.04% |
| CAC 40 | 7,934.70 | 61.59 | 0.78% |
| DAX 40 | 25,382.62 | 84.01 | 0.33% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,840.35 | 115.49 | 1.08% |
| HKSE | 24,371.66 | 308.94 | 1.28% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,550.68 | 1,124.73 | 1.75% |
| NZX 50 Index | 13,757.92 | 74.88 | -0.54% |
| S&P 500 | 7,744.06 | 25.12 | 0.33% |
| S&P/ASX 200 | 8,798.30 | 78.60 | 0.90% |
| SSE Composite Index | 3,735.65 | 28.18 | 0.76% |